First-pass extracted concept

Chimeric antigen receptor (CAR)-based immunotherapy

Candidate: concept label1 source documents5 linked claims

Jump to evidence Jump to sources Jump to claims

Live refresh every 5sNext refresh in 5s

Aliases

CAR-based immunotherapy

Evidence Snippets

Chimeric antigen receptor (CAR)-based immunotherapy has emerged as a transformative strategy in anticancer treatment

Evidence 1Source 1DOI PubMedprovenance

Supporting Sources

Source 1primary paper2025MEDDOI PubMed

1 evidence snippet 5 linked claims Claim 1 Claim 2 Claim 3

Linked Claims

Claim 1goalsupports2025Source 1DOI PubMed

Updated strategies combined with critical evaluation of limitations are intended to support development of standardized, robust, and accessible CAR-based immunotherapies.

Claim 2limitationsupports2025Source 1DOI PubMed

Current CAR-based therapies face challenges including cytokine release syndrome, neurotoxicity, product inconsistency, and high cost and complexity of cell manufacturing.

Claim 3manufacturing variable effectsupports2025Source 1DOI PubMed

Cell source, gene delivery methods, expansion protocols, and CAR design significantly influence the safety, efficacy, and scalability of CAR-based therapies.

Claim 4scopesupports2025Source 1DOI PubMed

The review covers manufacturing protocols for CAR-modified T cells, NK cells, and unconventional T cell subsets including γδ T, iNKT, and MAIT cells.

Claim 5therapeutic statussupports2025Source 1DOI PubMed

CAR-based immunotherapy is presented as a transformative anticancer treatment strategy.